AHR and neoplasm: Fortunately, the release of NLG919 was responsible for inhibiting the Kyn-AHR channel, and restated the reversal of the tumor immunosuppression microenvironment, thus realizing intelligent nanovesicle-mediated chemoimmunotherapy cycle amplification in PDAC.